ORIC Pharmaceuticals 8-K Report: Key Updates for Investors - January 13, 2025
Based on the provided XML section of the financial report, here are the key insights and important information extracted:
- Entity Information:
- Company Name: ORIC Pharmaceuticals, Inc.
- CIK Number: 0001796280
- IRS Employer Identification Number (EIN): 47-1787157
- Address: 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080
- Contact Number: (650) 388-5600
- Filing Information:
- Filing Type: 8-K (Current Report)
- Filing Date: January 13, 2025
- Ticker Symbol:
- Stock Ticker: ORIC
- Exchange: NASDAQ
- Stock Information:
- Common Stock Par Value: $0.0001 per share
- Filing Context:
- The report pertains to a specific duration, with both the start and end date being January 13, 2025. This indicates that the information contained within the filing may be relevant for events or disclosures occurring on this specific date.
- Regulatory References:
- The report references an XBRL schema (oric-20250113.xsd), which is used for the structured data reporting to the SEC.
Insights:
- The filing date indicates that this report may contain timely information pertaining to recent developments or significant events related to ORIC Pharmaceuticals.
- As an 8-K filing, it is likely to disclose material events that shareholders should be aware of, which could influence stock performance or investor decisions.
- Given that ORIC Pharmaceuticals is listed on NASDAQ, it signals that the company is subject to regulatory scrutiny and reporting requirements typical for publicly traded companies.
This information can be critical for investors, analysts, and stakeholders monitoring the company’s performance and market position.